A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors BlackThorn Therapeutics
- 07 Dec 2017 According to a BlackThorn Therapeutics media release, interim data from the first 15 patients were presented during panel and poster sessions at the American College of Neuropsychopharmacology (ACNP) Annual Meeting 2017.
- 24 Jul 2017 According to a BlackThorn Therapeutics media release, first patient has been enrolled.
- 22 Jun 2017 New trial record